NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 23 04:00PM ET
2.29
Dollar change
+0.02
Percentage change
0.88
%
Index- P/E- EPS (ttm)-2.48 Insider Own38.70% Shs Outstand30.90M Perf Week7.01%
Market Cap93.58M Forward P/E- EPS next Y-0.47 Insider Trans5.61% Shs Float25.05M Perf Month-18.51%
Income-54.17M PEG- EPS next Q-0.20 Inst Own29.98% Short Float0.26% Perf Quarter-28.88%
Sales24.38M P/S3.84 EPS this Y58.60% Inst Trans35.81% Short Ratio1.52 Perf Half Y-36.03%
Book/sh-1.31 P/B- EPS next Y38.31% ROA-136.63% Short Interest0.07M Perf Year-24.92%
Cash/sh0.32 P/C7.07 EPS next 5Y- ROE- 52W Range1.87 - 5.24 Perf YTD-38.77%
Dividend Est.- P/FCF- EPS past 5Y-10.72% ROI- 52W High-56.30% Beta0.98
Dividend TTM- Quick Ratio0.59 Sales past 5Y-7.38% Gross Margin43.93% 52W Low22.46% ATR (14)0.29
Dividend Ex-Date- Current Ratio0.69 EPS Y/Y TTM11.34% Oper. Margin-99.62% RSI (14)42.04 Volatility10.24% 12.82%
Employees51 Debt/Eq- Sales Y/Y TTM-31.04% Profit Margin-222.23% Recom1.00 Target Price9.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q60.62% Payout- Rel Volume0.18 Prev Close2.27
Sales Surprise-7.32% EPS Surprise-4.00% Sales Q/Q-6.93% EarningsMar 06 AMC Avg Volume42.83K Price2.29
SMA20-5.94% SMA50-17.94% SMA200-34.51% Trades Volume7,591 Change0.88%
Date Action Analyst Rating Change Price Target Change
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
Apr-22-25 04:05PM
Apr-21-25 08:00AM
Apr-14-25 08:00AM
Apr-04-25 08:00AM
Apr-03-25 08:00AM
04:05PM Loading…
Apr-02-25 04:05PM
Mar-27-25 04:05PM
Mar-25-25 04:05PM
Mar-06-25 04:05PM
Mar-05-25 07:30AM
Feb-20-25 04:05PM
Feb-03-25 06:30AM
Jan-15-25 08:15AM
Jan-14-25 08:00AM
Jan-06-25 08:00AM
08:00AM Loading…
Dec-02-24 08:00AM
Nov-14-24 04:05PM
Nov-13-24 04:05PM
07:27AM
Oct-29-24 04:05PM
Oct-23-24 04:05PM
Oct-17-24 04:15PM
Oct-15-24 11:01AM
Sep-18-24 08:00AM
Sep-06-24 04:23PM
Sep-05-24 04:05PM
Sep-03-24 04:05PM
Aug-21-24 07:00AM
Aug-20-24 07:00AM
Aug-07-24 04:05PM
04:05PM Loading…
Aug-01-24 04:05PM
Jul-31-24 04:05PM
Jul-30-24 04:05PM
Jul-17-24 04:15PM
07:00AM
Jul-16-24 07:00AM
Jul-11-24 04:05PM
03:24PM
Jun-17-24 08:01AM
08:00AM
May-13-24 08:00AM
May-09-24 10:55PM
04:05PM
May-02-24 04:05PM
Apr-29-24 09:00AM
Apr-24-24 04:05PM
Mar-07-24 09:53PM
04:05PM
Feb-22-24 04:05PM
Feb-20-24 10:37AM
Jan-10-24 04:05PM
Dec-18-23 08:00AM
Nov-13-23 04:05PM
Nov-09-23 08:30AM
Nov-06-23 04:05PM
Oct-18-23 08:00AM
Sep-20-23 08:30AM
Sep-19-23 08:36AM
Sep-18-23 04:08PM
Sep-08-23 08:30AM
Sep-06-23 04:05PM
Aug-30-23 08:30AM
Aug-21-23 09:42AM
Aug-15-23 05:21AM
Aug-14-23 04:05PM
Jul-31-23 04:05PM
Jul-26-23 03:29PM
Jul-17-23 04:05PM
Jul-13-23 04:30PM
May-19-23 01:45PM
08:15AM
May-13-23 08:17AM
May-11-23 09:58AM
05:51AM
May-10-23 04:05PM
May-03-23 04:05PM
10:42AM
Apr-20-23 04:30PM
Apr-17-23 06:11AM
Apr-05-23 09:55AM
Mar-27-23 06:26AM
Mar-23-23 06:08AM
Mar-22-23 04:01PM
08:30AM
Mar-20-23 12:01PM
08:00AM
Mar-15-23 04:05PM
Feb-27-23 08:15AM
Jan-31-23 08:00AM
Jan-26-23 12:00PM
09:40AM
Jan-21-23 09:58AM
Jan-09-23 08:15AM
Dec-15-22 08:00AM
Dec-10-22 07:38AM
Dec-01-22 09:04AM
Nov-30-22 04:08PM
Nov-21-22 04:05PM
Nov-16-22 06:00AM
Nov-14-22 05:25PM
Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. It operates through the following segments: Device Protection, Women's Health, and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Cardiovascular segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HighCape Capital, L.P.DirectorFeb 03 '25Buy2.50420,0001,050,0009,520,232Mar 13 04:30 PM
HighCape Capital, L.P.DirectorFeb 03 '25Buy2.50420,0001,050,0009,520,232Mar 13 04:28 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERJul 31 '24Option Exercise1.43105,080150,002257,823Jul 31 05:00 PM